The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Sequana Medical Announces 2017 AASLD Poster Presentation

Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that it will have a poster presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held October 20-24 in Washington, DC.
Dr. Gijs Klarenbeek,MD, Chief Medical Officer for Sequana Medical, commented, “This poster will be presented on Monday October 23 by Prof. Florence Wong, University of Toronto, Toronto General Hospital. It is the first time data are released from the MOSAIC study and primary and secondary safety and efficacy endpoints, including an analysis of the impact on the Quality of Life (QoL) will be presented.
Ian Crosbie, Chief Executive Officer of Sequana Medical added, “We are very pleased the results from this first North American trial can be shared with the scientific community and to demonstrate that the alfapump® delivers important benefits with this key complication of liver disease. Through our ongoing development work and close collaboration with clinicians, we continue to grow the body of evidence of the impact of the alfapump® in this patient population, as shown by the multiple recent peer-reviewed journal publications, and of course the data from the MOSAIC study to be presented during AASLD 2017.”

Poster # 1790

Title: ‘Improvement in Quality of Life and Reduction in Large Volume Paracentesis Requirement from the MOSAIC study: a Multicenter, Open-Label, Prospective 3-month Study of the Alfapump System in Refractory Ascites’

Poster Session IV
Date: Monday, October 23, 2017
Time: 12:30pm – 2:00PM
Presenter: Prof. Florence Wong Division of Gastroenterology, Department of Medicine, University of Toronto

Related Posts